I am very interested by the highlighted one. That will likely be done by a US-based life sciences professional services or consulting firm that probably serves many big pharma clients. They would be credible and imo it's likely they do similar work for big names. I suspect this will add some more legitimacy to partnership/buyout discussions and will add a lot of value to shareholders. Keen to see the results.
Ann: Race 2022 AGM Presentations, page-4
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |